nintedanib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiogenesis inhibitors 4903 656247-17-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BIBF1120
  • nibtedanib
  • nintedanib
  • nintedanib esylate
  • intedanib
  • BIBF 1120
  • ofev
  • nintedanib ethanesulfonate
  • vargatef
  • Molecular weight: 539.64
  • Formula: C31H33N5O4
  • CLOGP: 3.08
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 94.22
  • ALOGS: -4.24
  • ROTB: 8

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.38 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 3, 2015 PMDA Boehringer Ingelheim
Oct. 15, 2014 FDA BOEHRINGER INGELHEIM
Nov. 20, 2014 EMA Boehringer Ingelheim International GmbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 976.93 22.91 934 11917 714432 62761739
Nausea 318.93 22.91 594 12257 853877 62622294
Decreased appetite 266.39 22.91 289 12562 250763 63225408
Malignant neoplasm progression 242.80 22.91 170 12681 81951 63394220
Vomiting 242.07 22.91 416 12435 559201 62916970
Death 160.73 22.91 278 12573 374103 63102068
Weight decreased 123.09 22.91 209 12642 276589 63199582
Drug ineffective 102.72 22.91 42 12809 1044723 62431448
Dyspnoea 97.69 22.91 324 12527 660989 62815182
Drug-induced liver injury 78.30 22.91 65 12786 40157 63436014
Cough 68.91 22.91 170 12681 292573 63183598
Flatulence 67.37 22.91 56 12795 34646 63441525
Gamma-glutamyltransferase increased 62.12 22.91 53 12798 33978 63442193
Mucosal infection 61.95 22.91 13 12838 189 63475982
Idiopathic pulmonary fibrosis 61.31 22.91 19 12832 1373 63474798
Constipation 57.57 22.91 135 12716 224808 63251363
Liver disorder 55.20 22.91 61 12790 53626 63422545
Oxygen saturation decreased 50.38 22.91 75 12776 88510 63387661
Dyspnoea exertional 47.84 22.91 60 12791 60242 63415929
Pneumothorax 46.40 22.91 33 12818 16228 63459943
Hepatotoxicity 45.00 22.91 46 12805 36995 63439176
Liver function test increased 44.01 22.91 43 12808 32768 63443403
Drug hypersensitivity 40.64 22.91 7 12844 310680 63165491
Epistaxis 40.52 22.91 61 12790 72664 63403507
Pulmonary hypertension 39.57 22.91 43 12808 37080 63439091
Infusion related reaction 38.36 22.91 3 12848 245518 63230653
Productive cough 36.62 22.91 54 12797 63154 63413017
Pulmonary embolism 36.55 22.91 76 12775 116608 63359563
Arthropathy 36.31 22.91 3 12848 234789 63241382
Hepatic function abnormal 36.11 22.91 41 12810 37101 63439070
Aspartate aminotransferase increased 35.84 22.91 65 12786 90212 63385959
Faeces soft 35.42 22.91 19 12832 5673 63470498
Abnormal loss of weight 35.14 22.91 19 12832 5763 63470408
Respiratory failure 35.06 22.91 69 12782 101789 63374382
Alanine aminotransferase increased 34.16 22.91 69 12782 103701 63372470
Joint swelling 33.92 22.91 12 12839 327654 63148517
Abdominal pain upper 33.69 22.91 105 12746 206339 63269832
Product use issue 33.60 22.91 3 12848 220517 63255654
Interstitial lung disease 33.17 22.91 51 12800 61857 63414314
Pain 32.59 22.91 63 12788 740565 62735606
White blood cell count decreased 29.73 22.91 78 12773 139026 63337145
Swelling 28.64 22.91 10 12841 275368 63200803
Arthralgia 28.17 22.91 45 12806 569665 62906506
Intestinal haemorrhage 27.23 22.91 14 12837 3833 63472338
Metastases to central nervous system 27.21 22.91 22 12829 13083 63463088
Neutrophil count decreased 26.82 22.91 44 12807 56362 63419809
Rheumatoid arthritis 26.77 22.91 9 12842 253810 63222361
Hypersensitivity 26.61 22.91 13 12838 292672 63183499
Disease progression 26.40 22.91 69 12782 122689 63353482
Transaminases increased 26.13 22.91 32 12819 31335 63444836
Large intestine perforation 26.03 22.91 18 12833 8464 63467707
Stomatitis 25.87 22.91 74 12777 138651 63337520
Pneumomediastinum 25.68 22.91 10 12841 1426 63474745
Pneumonia 24.42 22.91 167 12684 456600 63019571
Total lung capacity abnormal 23.81 22.91 5 12846 73 63476098
Dairy intolerance 23.56 22.91 5 12846 77 63476094
Haemoptysis 23.44 22.91 29 12822 28697 63447474
Fatigue 23.36 22.91 278 12573 887750 62588421

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1491.64 19.90 1333 15729 388579 34551290
Malignant neoplasm progression 440.44 19.90 355 16707 87691 34852178
Decreased appetite 351.43 19.90 418 16644 165974 34773895
Death 259.82 19.90 586 16476 397463 34542406
Weight decreased 246.40 19.90 362 16700 175939 34763930
Pneumothorax 188.69 19.90 117 16945 18975 34920894
Dyspnoea 176.90 19.90 490 16572 376292 34563577
Lung transplant 151.21 19.90 51 17011 1973 34937896
Nausea 137.94 19.90 420 16642 339488 34600381
Cough 118.82 19.90 240 16822 149900 34789969
Faeces soft 87.80 19.90 40 17022 3468 34936401
Abnormal loss of weight 84.96 19.90 41 17021 4049 34935820
Productive cough 80.93 19.90 96 16966 37717 34902152
Respiratory failure 73.50 19.90 163 16899 108409 34831460
Liver disorder 70.98 19.90 84 16978 32913 34906956
Idiopathic pulmonary fibrosis 69.12 19.90 34 17028 3500 34936369
Drug-induced liver injury 64.68 19.90 75 16987 28757 34911112
Drug ineffective 61.55 19.90 80 16982 456671 34483198
Abdominal pain upper 58.44 19.90 116 16946 71374 34868495
Pulmonary fibrosis 53.73 19.90 55 17007 18341 34921528
Pulmonary embolism 53.27 19.90 128 16934 89618 34850251
Pulmonary function test decreased 50.40 19.90 31 17031 4944 34934925
Chronic respiratory failure 47.83 19.90 20 17042 1409 34938460
Lung neoplasm malignant 47.20 19.90 50 17012 17345 34922524
Hepatic enzyme increased 46.85 19.90 75 16987 39005 34900864
Constipation 46.73 19.90 160 16902 136822 34803047
Pulmonary hypertension 46.20 19.90 54 17008 20870 34918999
Oxygen saturation decreased 45.99 19.90 89 16973 53729 34886140
Drug interaction 45.49 19.90 27 17035 225919 34713950
Toxicity to various agents 44.66 19.90 21 17041 200341 34739528
Abdominal discomfort 44.04 19.90 93 16969 59742 34880127
Gastrointestinal disorder 41.86 19.90 66 16996 33882 34905987
Vomiting 41.84 19.90 234 16828 247387 34692482
Flatulence 40.75 19.90 51 17011 21147 34918722
Forced vital capacity decreased 40.57 19.90 15 17047 761 34939108
Off label use 37.94 19.90 94 16968 419430 34520439
Pneumonia 37.91 19.90 304 16758 362323 34577546
Acute kidney injury 37.39 19.90 57 17005 304931 34634938
Fatigue 36.20 19.90 306 16756 370347 34569522
Pneumonia bacterial 35.58 19.90 36 17026 11836 34928033
Dyspnoea exertional 35.06 19.90 70 16992 43209 34896660
Hepatic function abnormal 35.04 19.90 71 16991 44292 34895577
Stomatitis 34.73 19.90 69 16993 42445 34897424
Completed suicide 34.04 19.90 4 17058 98164 34841705
Pneumomediastinum 32.59 19.90 18 17044 2349 34937520
General physical health deterioration 32.27 19.90 136 16926 128133 34811736
Dysgeusia 31.95 19.90 51 17011 26446 34913423
Oxygen consumption increased 29.29 19.90 14 17048 1352 34938517
Epistaxis 29.22 19.90 78 16984 58173 34881696
Metastases to central nervous system 28.55 19.90 27 17035 8178 34931691
Haemoglobin decreased 27.91 19.90 12 17050 120760 34819109
Overdose 26.47 19.90 6 17056 91053 34848816
Drug hypersensitivity 26.20 19.90 4 17058 80525 34859344
Colitis ischaemic 25.82 19.90 23 17039 6452 34933417
Hypotension 25.64 19.90 43 17019 221606 34718263
Confusional state 25.28 19.90 20 17042 144140 34795729
Haemoptysis 25.27 19.90 54 17008 34952 34904917
Product use in unapproved indication 25.11 19.90 13 17049 117486 34822383
Product dose omission issue 24.49 19.90 14 17048 119697 34820172
Interstitial lung disease 23.76 19.90 78 16984 65204 34874665
Coating in mouth 23.48 19.90 6 17056 85 34939784
Splenic vein thrombosis 23.44 19.90 9 17053 507 34939362
Liver function test increased 23.27 19.90 32 17030 14533 34925336
Polyneuropathy 22.71 19.90 32 17030 14864 34925005
Mesenteric vein thrombosis 22.25 19.90 10 17052 839 34939030
Post procedural pneumonia 21.69 19.90 6 17056 117 34939752
Product use issue 20.89 19.90 3 17059 63213 34876656
Bradycardia 19.95 19.90 6 17056 75412 34864457

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 2062.82 18.04 1940 24753 878549 78839146
Malignant neoplasm progression 801.23 18.04 522 26171 135468 79582227
Decreased appetite 564.96 18.04 631 26062 341787 79375908
Death 505.04 18.04 770 25923 565744 79151951
Nausea 336.51 18.04 881 25812 956315 78761380
Weight decreased 314.04 18.04 482 26211 354716 79362979
Pneumothorax 241.36 18.04 138 26555 28185 79689510
Dyspnoea 211.83 18.04 697 25996 856328 78861367
Vomiting 194.23 18.04 574 26119 665254 79052441
Drug-induced liver injury 136.96 18.04 138 26555 65979 79651716
Drug ineffective 133.23 18.04 101 26592 1080812 78636883
Cough 124.89 18.04 335 26358 366454 79351241
Liver disorder 123.03 18.04 136 26557 72281 79645414
Faeces soft 117.89 18.04 57 26636 8266 79709429
Lung transplant 115.64 18.04 47 26646 4514 79713181
Idiopathic pulmonary fibrosis 105.25 18.04 43 26650 4185 79713510
Constipation 103.89 18.04 266 26427 282784 79434911
Flatulence 101.21 18.04 96 26597 42628 79675067
Respiratory failure 99.87 18.04 200 26493 180711 79536984
Pulmonary embolism 93.82 18.04 189 26504 171465 79546230
Toxicity to various agents 88.42 18.04 17 26676 421523 79296172
Abnormal loss of weight 79.98 18.04 44 26649 8332 79709363
Hepatic function abnormal 78.44 18.04 109 26584 72998 79644697
Drug hypersensitivity 72.01 18.04 8 26685 298908 79418787
Productive cough 69.55 18.04 114 26579 88217 79629478
Pulmonary hypertension 69.33 18.04 83 26610 47997 79669698
Dyspnoea exertional 66.70 18.04 111 26582 86962 79630733
Abdominal pain upper 65.77 18.04 194 26499 223625 79494070
Oxygen saturation decreased 65.65 18.04 138 26555 128909 79588786
Infusion related reaction 64.43 18.04 3 26690 230234 79487461
Gamma-glutamyltransferase increased 63.91 18.04 85 26608 54595 79663100
Pneumonia 61.96 18.04 405 26288 659841 79057854
Epistaxis 61.14 18.04 123 26570 111392 79606303
Pneumomediastinum 57.69 18.04 27 26666 3640 79714055
Mucosal infection 56.54 18.04 16 26677 503 79717192
Stomatitis 55.90 18.04 140 26553 146617 79571078
Forced vital capacity decreased 54.84 18.04 21 26672 1722 79715973
Off label use 53.47 18.04 143 26550 907072 78810623
Interstitial lung disease 53.34 18.04 117 26576 112483 79605212
Haemoptysis 52.02 18.04 78 26615 55921 79661774
Joint swelling 51.97 18.04 16 26677 288630 79429065
Metastases to central nervous system 51.08 18.04 43 26650 16332 79701363
Lung neoplasm malignant 50.31 18.04 54 26639 27738 79689957
Fatigue 49.92 18.04 502 26191 929225 78788470
Chronic respiratory failure 49.87 18.04 23 26670 2999 79714696
Liver function test increased 49.85 18.04 64 26629 39709 79677986
Product use issue 49.55 18.04 6 26687 209816 79507879
Pulmonary function test decreased 48.93 18.04 31 26662 7606 79710089
Musculoskeletal stiffness 46.72 18.04 3 26690 175005 79542690
General physical health deterioration 46.60 18.04 199 26494 275039 79442656
Pain 46.06 18.04 105 26588 703697 79013998
Arthralgia 45.46 18.04 76 26617 571727 79145968
Treatment failure 45.29 18.04 3 26690 170483 79547212
White blood cell count decreased 44.99 18.04 152 26541 188136 79529559
Neutrophil count decreased 44.92 18.04 98 26595 93861 79623834
Arthropathy 44.56 18.04 4 26689 177107 79540588
Drug interaction 42.28 18.04 46 26647 415137 79302558
Condition aggravated 42.28 18.04 64 26629 501060 79216635
Hepatotoxicity 41.38 18.04 67 26626 51285 79666410
Polyneuropathy 40.36 18.04 45 26648 24106 79693589
Confusional state 39.85 18.04 29 26664 317968 79399727
Pneumonia bacterial 39.36 18.04 40 26653 19291 79698404
Swelling 39.02 18.04 12 26681 216699 79500996
Taste disorder 38.31 18.04 36 26657 15787 79701908
Pneumonitis 38.07 18.04 71 26622 60789 79656906
Pulmonary fibrosis 37.53 18.04 59 26634 44053 79673642
Metastases to meninges 37.39 18.04 20 26673 3581 79714114
Hypersensitivity 36.83 18.04 21 26672 262218 79455477
Product dose omission issue 34.51 18.04 20 26673 247517 79470178
Transaminases increased 34.42 18.04 62 26631 51681 79666014
Peripheral sensory neuropathy 34.17 18.04 31 26662 13002 79704693
Disease progression 34.08 18.04 137 26556 184225 79533470
Oxygen consumption increased 33.88 18.04 21 26672 4958 79712737
Overdose 33.52 18.04 10 26683 184196 79533499
Large intestine perforation 33.10 18.04 32 26661 14535 79703160
Asthma 31.55 18.04 4 26689 135091 79582604
Intestinal haemorrhage 31.31 18.04 22 26671 6404 79711291
Haemoglobin decreased 30.88 18.04 18 26675 222101 79495594
Gastrooesophageal reflux disease 29.28 18.04 89 26604 104157 79613538
Abdominal discomfort 29.25 18.04 163 26530 250564 79467131
Total lung capacity abnormal 29.02 18.04 8 26685 228 79717467
Rheumatoid arthritis 28.83 18.04 17 26676 208453 79509242
Wound 28.23 18.04 3 26690 116176 79601519
Febrile neutropenia 27.49 18.04 151 26542 230848 79486847
Hepatic enzyme increased 26.35 18.04 126 26567 182484 79535211
Bradycardia 25.32 18.04 7 26686 135550 79582145
Dehydration 24.84 18.04 155 26538 248032 79469663
Pericarditis 24.55 18.04 3 26690 104233 79613462
Diarrhoea haemorrhagic 24.45 18.04 26 26667 13208 79704487
Hypotension 23.91 18.04 72 26621 440245 79277450
Weight increased 23.77 18.04 35 26658 277351 79440344
Coating in mouth 23.34 18.04 7 26686 271 79717424
Performance status decreased 23.19 18.04 18 26675 6095 79711600
Pemphigus 23.13 18.04 3 26690 99579 79618116
Post procedural pneumonia 22.99 18.04 6 26687 138 79717557
Sinusitis 22.98 18.04 19 26674 195482 79522213
Hypoxia 22.59 18.04 81 26612 103162 79614533
KL-6 increased 22.33 18.04 6 26687 155 79717540
Depressed level of consciousness 22.23 18.04 3 26690 96649 79621046
Malignant neoplasm of pleura 22.04 18.04 6 26687 163 79717532
Diverticulitis 22.04 18.04 48 26645 45888 79671807
Product use in unapproved indication 22.03 18.04 31 26662 250328 79467367
Acute respiratory failure 21.81 18.04 56 26637 59485 79658210
Dysgeusia 21.17 18.04 54 26639 57123 79660572
Dermatitis acneiform 20.93 18.04 21 26672 9972 79707723
Agitation 20.91 18.04 4 26689 99711 79617984
Discomfort 20.80 18.04 8 26685 125609 79592086
Dairy intolerance 20.76 18.04 5 26688 82 79717613
Pneumothorax spontaneous 20.72 18.04 10 26683 1444 79716251
Aspartate aminotransferase increased 20.24 18.04 96 26597 138545 79579150
Neutropenic sepsis 20.04 18.04 34 26659 27030 79690665
Hypoglycaemia 19.44 18.04 5 26688 101589 79616106
Systemic scleroderma 19.41 18.04 9 26684 1188 79716507
Tumour pain 19.03 18.04 11 26682 2288 79715407
Obstruction gastric 18.85 18.04 10 26683 1760 79715935
Somnolence 18.72 18.04 32 26661 238949 79478746
Alanine aminotransferase increased 18.48 18.04 105 26588 162465 79555230
Anaphylactic reaction 18.34 18.04 3 26690 83740 79633955
Asthenia 18.30 18.04 256 26437 511433 79206262
Urticaria 18.29 18.04 21 26672 185180 79532515
Faeces discoloured 18.23 18.04 34 26659 29093 79688602

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX09 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:63457 FGFR inhibitors
CHEBI has role CHEBI:65207 vascular endothelial growth factor receptor inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Interstitial fibrosis indication 125565008
Systemic sclerosis associated interstitial lung disease indication 233703007 DOID:3082
Non-small cell lung cancer indication 254637007 DOID:3908
Idiopathic pulmonary fibrosis indication 700250006 DOID:0050156




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.97 acidic
pKa2 7.77 Basic
pKa3 3.25 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL 10154990 Jan. 8, 2026 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL 10154990 Jan. 8, 2026 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL March 9, 2023 TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL March 9, 2023 TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2026 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2026 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Fibroblast growth factor receptor 3 Kinase INHIBITOR Kd 7.03 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.82 CHEMBL CHEMBL
Fibroblast growth factor receptor 2 Kinase INHIBITOR Kd 6.46 CHEMBL CHEMBL
Fibroblast growth factor receptor 4 Kinase INHIBITOR Kd 5.74 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 6.98 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR IC50 8.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 8.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 7.75 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Fibroblast growth factor receptor 1 Kinase INHIBITOR IC50 7.42 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Breakpoint cluster region protein Kinase Kd 6.52 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 8.21 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 7.10 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 6.20 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.54 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 9.38 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 8.02 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.32 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 7.19 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 6.59 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.85 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 7.21 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 6.54 CHEMBL
Insulin receptor Kinase AGONIST Kd 7.62 CHEMBL
Death-associated protein kinase 3 Kinase Kd 5.68 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 5.23 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 6.20 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.68 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.28 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 8.32 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 6.57 CHEMBL
Death-associated protein kinase 2 Kinase Kd 5.49 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 8.35 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 7.85 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.40 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.85 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 7.20 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 5.85 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 6.70 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.03 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 7.24 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 7.06 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 7.28 CHEMBL
Aurora kinase C Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 7.74 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 7.66 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.13 CHEMBL
Protein kinase C theta type Kinase Kd 5.26 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 6.96 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.03 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.28 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 6.64 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.52 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 7.51 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.07 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 8.66 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.57 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 8.06 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 6.12 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 6.41 CHEMBL
Glycogen synthase kinase-3 beta Kinase Kd 7.08 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.26 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 5.66 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 7.68 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 8.05 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.80 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 6.70 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.29 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 7.74 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 6.04 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 6.11 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 6.20 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 6.59 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.92 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.96 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.21 CHEMBL
Activin receptor type-1B Kinase Kd 5.31 CHEMBL
Serine/threonine-protein kinase receptor R3 Kinase Kd 5.38 CHEMBL
Activin receptor type-1 Kinase Kd 6.22 CHEMBL
3-phosphoinositide-dependent protein kinase 1 Kinase Kd 5.55 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 8 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 7.38 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 6.68 CHEMBL
Tyrosine-protein kinase ZAP-70 Kinase Kd 5.46 CHEMBL
Glycogen synthase kinase-3 alpha Kinase Kd 6.37 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 6.51 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 7.92 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 7.72 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 5.31 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.52 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.11 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.42 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 6.64 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 7.68 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.68 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 7.43 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 6.54 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 6.68 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 7.03 CHEMBL
Cyclin-dependent kinase 18 Kinase Kd 6.29 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 6.33 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 7.31 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Kinase Kd 7.77 CHEMBL
Myosin light chain kinase family member 4 Kinase Kd 6.36 CHEMBL
Wee1-like protein kinase Kinase Kd 5.54 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 7.09 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 7.64 CHEMBL
Casein kinase I isoform delta Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.66 CHEMBL
NT-3 growth factor receptor Kinase Kd 7.49 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 6.07 CHEMBL
Casein kinase II subunit alpha Kinase Kd 5.12 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.05 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B Kinase Kd 5.80 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.77 CHEMBL
Serine/threonine-protein kinase STK11 Kinase Kd 7.74 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.68 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 8.31 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 7.31 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.70 CHEMBL
Insulin receptor-related protein Kinase Kd 7.68 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 5.28 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 7.44 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.55 CHEMBL
SRSF protein kinase 1 Kinase Kd 7.43 CHEMBL
SRSF protein kinase 2 Kinase Kd 7.44 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.96 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2 Kinase Kd 7.08 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.38 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase LATS2 Kinase Kd 6.42 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 6.82 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.46 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 5.89 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 6.80 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.54 CHEMBL
Aurora kinase B Kinase Kd 6.38 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.42 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 7.25 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase MARK1 Kinase Kd 5.85 CHEMBL
MAP/microtubule affinity-regulating kinase 4 Kinase Kd 5.70 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.43 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 8.07 CHEMBL
Calcium/calmodulin-dependent protein kinase type IV Kinase Kd 5.43 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 6.66 CHEMBL
Mitogen-activated protein kinase kinase kinase 10 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 6.15 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 6.96 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.23 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.27 CHEMBL
Myosin-IIIb Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase PAK 2 Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.52 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 6.84 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 6.17 CHEMBL
TGF-beta receptor type-1 Kinase Kd 5.38 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.92 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 6.14 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.19 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 5.92 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 5.43 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 6.74 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 6.21 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 6.54 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.09 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.82 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 6.09 CHEMBL
Cyclin-dependent kinase 4 Kinase Kd 6.80 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.70 CHEMBL
Rhodopsin kinase Kinase Kd 6 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 7.77 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 5.92 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 6.10 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.07 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ICK Kinase Kd 5.77 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase Kd 5.35 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 6.92 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 8.03 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 7.47 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 5.34 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 5.44 CHEMBL
SRSF protein kinase 3 Kinase Kd 7.92 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 6.28 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 8.39 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 6.42 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 7.22 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 8.28 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.85 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 6.36 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.09 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase PRP4 homolog Kinase Kd 8.08 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase Sgk3 Kinase Kd 6 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.74 CHEMBL
Myosin light chain kinase 3 Kinase Kd 6.96 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.43 CHEMBL
cGMP-dependent protein kinase 1 Kinase Kd 7.85 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.06 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 8.09 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 8.59 CHEMBL
Multidrug resistance protein 1 Transporter EC50 6.56 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 7.14 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 8 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 8.57 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 5.92 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 7.89 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 8.44 CHEMBL

External reference:

IDSource
G6HRD2P839 UNII
D10396 KEGG_DRUG
4033814 VUID
N0000191096 NUI
656247-18-6 SECONDARY_CAS_RN
4033814 VANDF
C2930789 UMLSCUI
CHEBI:85164 CHEBI
CHEMBL502835 ChEMBL_ID
135423438 PUBCHEM_CID
DB09079 DRUGBANK_ID
CHEMBL3039504 ChEMBL_ID
9229 INN_ID
C530716 MESH_SUPPLEMENTAL_RECORD_UI
5936 IUPHAR_LIGAND_ID
1592736 RXNORM
229920 MMSL
30617 MMSL
d08301 MMSL
015720 NDDF
015723 NDDF
712494002 SNOMEDCT_US
715613009 SNOMEDCT_US
863993005 SNOMEDCT_US
XIN PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0143 CAPSULE 100 mg ORAL NDA 31 sections
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0143 CAPSULE 100 mg ORAL NDA 31 sections
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0145 CAPSULE 150 mg ORAL NDA 31 sections
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0145 CAPSULE 150 mg ORAL NDA 31 sections